Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1174273 | 0.88 | NPSR1 (0.49) | NPSR1THRATHRBS1PR1FFAR4 | |
| SCHEMBL14988768 | 0.82 | NPSR1 (0.57) | NPSR1THRATHRBS1PR1FFAR4 | |
| SCHEMBL21473664 | 0.80 | NPSR1 (0.47) | NPSR1THRATHRBS1PR1FFAR4 | |
| SCHEMBL6263548 | 0.80 | NPSR1 (0.55) | NPSR1THRATHRBS1PR1FFAR4 | |
| SCHEMBL1964714 | 0.78 | NPSR1 (0.53) | NPSR1THRATHRBS1PR1FFAR4 | |
| SCHEMBL145533 | 0.77 | TSHR (0.50) | FFAR4GPR17FFAR1GAA | |
| SCHEMBL27975056 | 0.76 | NPSR1 (0.50) | NPSR1THRATHRBS1PR1GPR17 | |
| SCHEMBL1856998 | 0.76 | NPSR1 (0.50) | NPSR1THRATHRBS1PR1GPR17 | |
| SCHEMBL1858828 | 0.75 | ACHE (0.37) | NPSR1 | |
| Ammonia Solution, Strong SCHEMBL28790127 | 0.74 | NPSR1 (0.48) | NPSR1THRATHRBS1PR1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101180290-B | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD | 2012-12-12 | — | — | CN | disclosed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-7981924-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-08-12 | — | — | US | disclosed |
| US-7723378-B2 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20080300294-A1 | Novel Thiophene Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-12-04 | — | — | US | disclosed |
| CN-101312959-A | Novel thiophene derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-26 | — | — | CN | disclosed |
| EP-1954688-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-07-24 | — | — | US | disclosed |
| CN-101180290-A | Hydogrenated benzo[c] thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-14 | — | — | CN | disclosed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007060626-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204198-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | NFATC1, ICOS, TPMT | NPSR1 1208/4885THRA 3112/4885THRB 2558/4885 |
| US-20080300294-A1 | Novel Thiophene Derivatives | TPMT, TSLP, NFATC1 | NPSR1 2553/4885THRA 3477/4885THRB 2617/4885 |
| US-20080176926-A1 | G protein-coupled receptor S1P1/EDG1 agonists; 3-(4-hydroxy-3,5-dimethyl-phenyl)-1-(3,5,5-trimethyl-4,5,6,7-tetrahydro-benzo[c]thiophen-1-yl)-propan-1-one; transplant rejection, graft-versus-host diseases, autoimmune syndromes; side effects reduction; immunosuppressive agents; Crohn's disease | S1PR1, S1PR3, S1PR5 | NPSR1 463/4885THRA 598/4885THRB 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.